News
Qurgen real-time updates on corporate news, industry trends and exciting events, witnessing every step of growth.
News
Qurgen is happy to announce that the blood and biopsy tissue results of a late-stage of ocular melanoma patient indicated complete melanoma driver gene mutations repairment under a 9-month SON-DP treatment. This makes SON-DP the ONLY cancer therapy that can repair the somatic mutations of cancer driver genes.
Dr. Chai Yan Joins Qurgen/Fuent as Senior Vice President for BP，Qurgen, CEO，Suzhou Fuent Pharmaceutics and Board Secretary of Both Qurgen and Suzhou Fuent Pharmaceutics.
Qurgen has completed a long-term (over 8 years) in vivo animal study from 2018 to 2026, in which 3 male and 2 female Cynomolgus monkeys have been given 12 repeated high doses of SON-DP transcription-factor treatment within 28 day period and went under 5 physical examinations in the last 8 years. No teratoma or tumor has since been found in these monkeys.
Qurgen has successfully manufactured two batches of GMP-scale SON-DP anti-tumor transcription factor protein drug which have been used in US and China Phase I trials.
A non-small cell lung cancer patient who received SON-DP for 4 months has achieved a complete response in February 2025. By March 2026, a 14-month follow-up reported that the patient continued to maintain a complete remission.
The China CDE officially approved the investigational new drug application of Suzhou Fuent Pharmaceutcal Co., Ltd., with the CDE acceptance number: CXSL2400508.
Prof Wang was invited to attend Tigermed's ASCO Pre-Event Webinar as a Speaker to introduce Qurgen’s breakthrough cell converting cancer therapy and recent progress in its Phase I clinical trial.
no infusion related reaction (IRR) has occurred during the 48-hour continuous infusion by pump, this indicates a significantly enhanced safety of SON-DP treatment.
Qurgen has completed SON-DP treatment for multiple late-stage solid tumor patients for over 18-months at low dose levels (2-4.5 mg/kg) and observed continue tumor shrinkage after 18-month SON-DP treatment without teratoma
Qurgen expanded 4 additional hospitals (Sarah Cannon Research Institute Tennessee, HCA HealthONE Denver, California Research Institute, LLC, Allison, Curtis, Kingsley, Meoz, Michael & Sanchez, Prof. Corp., DBA Comprehensive Cancer Centers of Nevada).
Qurgen is happy to announce that the blood and biopsy tissue results of a late-stage of ocular melanoma patient indicated complete melanoma driver gene mutations repairment under a 9-month
Suzhou Fuent expanded 5 additional clinical hospitals in China (Shandong Cancer Hospital, The First Hospital of Lanzhou University, Beijing Go Broad Hospital, Sun Yat-sen University Cancer Center, The First Affiliated Hospital of Xi’an Jiaotong University).